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Objective: Poor ovarian response to ovarian hyperstimulation is one of the biggest challenges in assisted
reproduction technology. Although many stimulation protocols have been established to improve clinical
outcomes in poor ovarian responders (PORs), which protocol is the most effective remains controversial.
Luteal-phase ovarian stimulation (LPOS) has been used in normal ovarian responders with satisfactory
outcomes. However, the efﬁcacy of LPOS in PORs is unclear. This study aimed to compare the efﬁcacy of
LPOS and GnRH antagonist (GnRH-ant) in PORs.
Materials and methods: The clinical parameters in PORs who received LPOS (50 cycles in 39 patients) or
GnRH-ant (158 cycles in 123 patients) were compared.
Results: Compared with those in the GnRH-ant group, the PORs in the LPOS group showed signiﬁcantly
fewer basal antral follicles (3.1 ± 2.2 vs. 4.1 ± 1.6, p < 0.001) and a higher in vitro fertilization rate. There
were no signiﬁcant differences in the numbers of retrieved oocytes and D3 transferable embryos be-
tween the two groups. However, the pregnancy rate in the LPOS group (46.4%) was signiﬁcantly higher
than that in the GnRH-ant group (25.8% overall; 22.9% from fresh embryos and 29.6% from frozen em-
bryos). Moreover, 23 PORs in the LPOS group underwent oocyte retrieval twice in one cycle, and the
numbers of retrieved oocytes and transferable embryos from the luteal phase were signiﬁcantly higher
than those from the follicular phase in the same menstrual cycle.
Conclusions: Compared with the GnRH-ant protocol, the LPOS protocol may be a better regime for PORs
that can increase the numbers of retrieved oocytes and transferable embryos as well as the pregnancy
rate.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Assisted reproduction technology such as in vitro fertil-
izationeembryo transfer (IVFeET) has helped millions of sub-
fertile females to have their own babies, and ovarian stimulation is
considered to be the critical factor for clinical outcomes. Poor
ovarian response (POR) to controlled ovarian hyperstimulation is
one of the biggest challenges in assisted reproduction technologynter of Liuzhou Maternal &
000, China.
is study.
bstetrics & Gynecology. Publishedand has been reported to occur in 9e24% of women undergoing
IVF [1].
The European Society for Human Reproduction and Embryology
(ESHRE) deﬁnes a POR in IVF according to the presence of at least
two of the following three features: (1) advanced maternal age or
any other risk factor for POR; (2) a previous POR; and (3) an
abnormal ovarian reserve test [2]. Many stimulation protocols have
been established to improve clinical outcomes in PORs. Although
many related studies have been published, which protocol is the
most effective and preferable in PORs remains controversial [3e5].
It is well accepted that only one follicle is selected to mature in
each menstrual cycle, whereas the others undergo atresia [6].
Standard regimens of ovarian stimulation in IVF usually start fromby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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phase ovarian stimulation can cause serious complications such
as ovarian hyperstimulation syndrome, premature luteinization,
and suboptimal oocyte quality [3,4,7]. Therefore, GnRH analog
cotreatment is often used to prevent the premature luteinizing
hormone (LH) surge; however, this regimen makes the stimulation
complex [7]. Interestingly, some studies have demonstrated that
small antral follicles observed during the luteal phase may not
necessarily undergo atresia but instead remain in the early stages of
follicular development [8,9]. The detection of oocyte and granulosa
cell viability implicates the presence of healthy follicles in the luteal
phase. Previous studies demonstrated that the oocytes retrieved
during the luteal phase can be competent to mature and be fertil-
ized [10,11], which implicates the possibility that follicles are
continuously available for stimulation by Gn (gonadotropin) during
the menstrual cycle. Moreover, a recent study by Kuang et al [12]
initiated ovarian stimulation with hMG (human menopausal
gonadotropin) and letrozole during the luteal phase and achieved
satisfactory ovarian response and pregnancy outcome. This study
concluded that luteal-phase ovarian stimulation (LPOS) is feasible
for producing competent oocytes in women undergoing IVF/intra-
cytoplasmic sperm injection (ICSI) treatment [12]. However, the
efﬁcacy of LPOS in PORs compared with that of conventional pro-
tocols is unclear. In this retrospective study, we compared the
clinical data from PORs who received LPOS or GnRH antagonist
treatment at our center and further compared the quality of oocytes
retrieved during the luteal phase and follicular phase in the same
patient.
Materials and methods
Patients
Data were collected for a total of 162 PORs who underwent IVF/
ICSI treatment at the Assisted Reproduction Center of Liuzhou
Maternal & Child Health Hospital (Liuzhou, Guangxi, China) from
May 2013 to May 2014. This study was approved by the local ethics
committee of Liuzhou Maternal & Child Health Hospital, and oral
consent was obtained from all patients.
PORs were deﬁned when at least two of the following criteria
were met: (1) age >40 years, (2) prior history of poor response to
conventional long treatment with GnRH agonist (3 oocytes
retrieved), and (3) basal antral follicle count (AFC) <6. Also, all
patients had to have a body mass index between 18 and 28 kg/m2
and be without endometriosis and hydrosalpinx. According to
different treatment protocols, the patients were divided into two
groups: the LPOS group (50 cycles, 39 patients) and the GnRH
antagonist group (158 cycles, 123 patients) (Figure 1).
Protocols for ovarian stimulation
LPOS group
LPOS was carried out according to a previously described
protocol [13]. Brieﬂy, on the next day of oocyte retrieval (or
advanced ovulation) after mild stimulation or natural cycle, pa-
tients with follicles <10mm received 225 IM (intramuscular) hMG
(Livzon Pharmaceutical Group Inc., Zhuhai, China) and 2.5 mg/
d oral Letrozole (LE, Jiangsu Hengrui Medicine Co. Ltd., Lia-
nyunguang, China) or 50 mg/d oral clomifene citrate (CC; Codal
Synto Pharmaceuticals, Limassol, Cyprus). The initial follicular
monitoring started 5e7 days later and was performed every
2e4 days by transvaginal ultrasound examination to record the
number of developing follicles and measurement of serum
follicle-stimulating hormone (FSH), LH, estradiol, and progester-
one (P) concentrations. LE/CC administration was stopped whenthe dominant follicles reached 12 mm in diameter. Daily admin-
istration of 10 mg medroxyprogesterone acetate was added
beginning on stimulation Day 12 for cases in which the post-
ovulation follicle size was smaller than 14mm in diameter and the
stimulation needed to continue for several more days. When three
dominant follicles reached a diameter of 18 mm or one dominant
follicle exceeded 20 mm in diameter, the ﬁnal stage of oocyte
maturation was induced via an injection of 10,000 IU human
chorionic gonadotrophin (hCG).
For the mild stimulation protocol, the PORs received 2.5 mg/
d oral LE or 50 mg/d oral CC for 5 days from the 2nd or 3rd day of the
same menstrual period, followed by IM injection of 75e150 IU/
d hMG until the day of GnRH agonist (0.1 mg Diphereline; Ipsen
Pharma Biotech, Signes, France) administration to induce oocyte
maturation once there were three dominant follicles with a diam-
eter of 18 mm or one dominant follicle exceeding 20 mm in
diameter (Figure 2).
GnRH-ant group
The patients received IM injections of 150e225 IU/d hMG for
5 days from the 2nd or 3rd day of the menstrual period, and then the
hMG dose was adjusted according to the ovarian response and E2
level. From the 6th day of hMG injection, 0.25 mg/d cetrorelix ac-
etate (Baxter Oncology GmbH, Westfalen, Germany) was subcuta-
neously injected until the day of hCG administration. When three
dominant follicles reached a diameter of 18 mm or one mature
dominant follicle exceeded 20 mm in diameter, the ﬁnal stage of
oocyte maturation was induced with 10,000 IU hCG.
Oocyte retrieval and fertilization
Transvaginal ultrasound-guided oocyte retrieval was conducted
36e37 hours later after maturation inducement. In 27 cycles in
patients in the LPOS group, oocytes were retrieved at the follicular
phase and the luteal phase, whereas in another 23 cycles, oocytes
were only obtained at the luteal phase (with advanced ovulation in
the follicular phase). Fertilization was carried out in vitro, by either
conventional insemination or ICSI, depending on semen parame-
ters. Successful fertilization was deﬁned when two clear pronuclei
were present after 16e18 hours of insemination.
Embryo culture and transfer
The fertilized oocytes were cultured with G1.5 and G2.5
sequential media (Vitrolife, Kungsbacka, Sweden) at 37C with 6%
CO2 and 5% O2. On the 3rd day of fertilization, embryos were
graded according to the number and regularity of blastomeres and
the degree of embryonic fragmentation from Cummins's criteria
[14]. The high-quality embryos (grades 1 and 2) were transferred
freshly or frozen by vitriﬁcation on the 3rd day. If the embryos
were not of top quality, they were continuously cultured until the
blastocyst stage. On Day 5 or 6, the quality of blastocysts was
scored according to the Gardner blastocyst grading system. At this
stage, the blastocysts with >3BB grade were considered high
quality, whereas the blastocysts with >3CC gradewere transferred
or frozen.
ET in the GnRH-ant group was conducted on the 3rd or 5th day (if
a high-quality embryo was not available on Day 3). For ET in the
LPOS group, all available embryos were frozen. The procedure for
freezing and thawing embryos was carried out as previously
described [15]. Endometrial preparation and frozen ET were per-
formed in either a natural cycle or a stimulation cycle or a hormone
replacement therapy (HRT) cycle. For endometrial preparation in
the HRT cycle, oral 4e6 mg/d E2 (Bayer Pharma AG, Berlin, Ger-
many) was given from cycle Day 3 onward. Once the endometrial
Figure 1. Proﬁle summary of the pilot study. GnRH-ant ¼ gonadotrophin-releasing hormone antagonist; POR ¼ poor ovarian response.
Figure 2. The protocols for mild stimulation and luteal phase ovarian stimulation in patients with poor ovarian response. CC ¼ clomiphene; GnRH-a ¼ gonadotrophin-releasing
hormone agonist; hCG ¼ human chorionic gonadotrophin; HMG ¼ human menopausal gonadotrophin; LE ¼ letrozole; MPA, medroxyprogesterone acetate; OPU ¼ ovum-pick-up.
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Day 14 after ET, and ET was carried out on Day 4 or 6 after P in-
jection. The maximum number of transferred embryos was three
per patient. After ET in both groups, IM injection of 40 mg/d P
(natural cycle, stimulation cycle) or 60 mg/d P (HRT cycle) was
started. The outcome of pregnancy was ﬁrst examined on Day 14
after ET by measuring the blood hCG level and further veriﬁed on
Day 35 after ET by ultrasound. If pregnancy was achieved, P injec-
tion was continued until 8e10 weeks of gestation.
Statistical analysis
The datawere analyzed using SPSS 13.0 software, and some data
were presented as the mean ± standard deviation. The signiﬁcance
of clinical parameters between two groups was analyzed using Chi-
square test or Fisher's exact tests. Moreover, continuous variables
were analyzed by independent or paired t tests. A p value <0.05was
considered statistically signiﬁcant.Results
Comparison of clinical parameters between LPOS and GnRH-ant
groups
Therewere no signiﬁcant differences in patients' age, body mass
index, years of infertility, basal FSH levels, LH levels, and E2 levels
(Table 1). The basal AFC in the LPOS group was signiﬁcantly lower
than that in the GnRH-ant group. On the day of hCG administration,
compared with those in the GnRH-ant group, PORs in the LPOS
group showed signiﬁcantly reduced LH and increased P, but similar
levels of FSH and E2. None of PORs in the LPOS group had LH  10
IU/L, whereas 9.5% (15/158) of PORs in the GnRH-ant group
exhibited LH  10 IU/L. The total amount and days of Gn admin-
istration in the LPOS group were signiﬁcantly greater than those in
the GnRH-ant group, but there was no signiﬁcant difference in the
number of retrieved oocytes between the two groups (Table 1).
After ovarian stimulation, compared with GnRH-ant group, the rate
Table 1
Comparison of clinical parameters in the luteal-phase ovarian stimulation (LPOS)
and GnRH antagonist (GnRH-ant) groups.
Group LPOS (n ¼ 50) GnRH-ant
(n ¼ 1 58)
p
Baseline parameters
Age (y) 36.1 ± 4.4 36.7 ± 4.7 0.42
Duration of infertility (y) 6.1 ± 4.2 5.6 ± 4.0 0.43
BMI (kg/m2) 21.1 ± 3.8 21.6 ± 3.2 0.89
Cycles of previous treatment 2.3 ± 1.4 2.0 ± 1.3 0.16
Basal AFC 3.1 ± 2.2 4.1 ± 1.6 <0.001*
Basal serum FSH (IU/L) 9.8 ± 4.8 10.5 ± 5.2 0.42
Basal serum LH (IU/L) 4.6 ± 3.3 4.4 ± 3.4 0.60
Basal serum E2 (pg/L) 67.7 ± 69.8 54.4 ± 27.8 0.20
Duration of stimulation (d) 9.3 ± 4.3 7.7 ± 2.6 0.02*
Total Gn consumption (tube) 27.6 ± 12.8 19.6 ± 9.1 <0.001*
Hormone levels on the day of hCG administration
FSH (IU/L) 17.6 ± 5.5 17.9 ± 6.0 0.76
LH (IU/L) 3.0 ± 2.6 4.9 ± 5.2 <0.001*
E2 (pg/L) 1247.8 ± 1015.8 919.4 ± 571.7 0.21
P (ng/L) 12.8 ± 14.5 0.81 ± 0.85 <0.001*
Ratio of LH  10 IU/L 0 9.5% 0.026*
Outcome of ovarian stimulation
COCs retrieved 5.2 ± 5.6 4.0 ± 2.6 0.14
Rate of oocyte retrieval (%) 69.5 75.1 0.04*
Ratio of IVF/ICSI
application (%)
80.0/20.0 82.3/17.7 0.72
Maturation rate in ICSI
(M II, %)
79.2 83.5 0.50
Fertilization rate by ICSI (%) 86.8 83.8 0.65
Fertilization rate by IVF (%) 79.4 69.7 0.01*
D3 embryos available 3.3 ± 4.3 2.2 ± 1.7 0.08
The data are presented asmean ± SD. Basal AFC and basal FSH, LH and E2 levels were
measured on the 2nd to 5th days of the menstrual period. The data related to oocyte/
embryo parameters in the LPOS group were from the luteal phase. The percentage
data were analyzed by Chi-square test or Fisher's exact test, whereas other data
were analyzed with independent t test. *p < 0.05.
AFC ¼ antral follicle count; BMI ¼ body mass index; COCs ¼ cumulus oocyte com-
plexes; E2 ¼ estradiol; FSH ¼ follicle stimulating hormone; Gn, gonadotropin;
ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; LH ¼ luteinizing
hormone; P ¼ progesterone.
Table 2
Comparison of clinical outcomes of embryos from LPOS and GnRH-ant protocols.
LPOS
(ﬁrst FET)
GnRH-ant
Fresh embryo
transfer
First FET
Cancellation rate
(no available embryos)
(%, n)
17.9 (7/39) 16.3 (20/123)
Number of PORs with
embryos transferred
28 70 54
Ratio of transferred embryos
on Day 3/Day 5 (%)
85.7/14.3 100/0 88.9/11.1
Embryos transferred 2.1 ± 0.5 2.0 ± 0.6 2.1 ± 0.6
Implantation rate (%, n)
D3 embryos 23.5 (12/51) 12.9 (18/140) 16.0 (16/100)
D5 embryos 50.0 (4/8) d 18.2 (2/11)
Clinical pregnancy rate
(%, n)
46.4 (13/28) 22.9 (16/70)* 29.6 (16/54)
Spontaneous abortion
rate (%, n)
15.4 (2/13) 25 (4/16) 6.3 (1/16)
The data are presented as mean ± SD or ratio. The percentage data were analyzed by
Chi-square test or Fisher's exact test, whereas number of transferable embryos was
analyzed with independent t test. *p < 0.05 compared with LPOS.
FET ¼ frozen embryo transfer; GnRH-ant ¼ GnRH antagonist; LPOS ¼ luteal-phase
ovarian stimulation; PORs ¼ poor ovarian responders.
Table 3
Comparison of clinical parameters and outcomes of oocytes/embryos from the
follicular phase using mild stimulation and the luteal phase in one cycle.
Follicular phase
(n ¼ 23)
Luteal phase
(n ¼ 23)
p
Outcome of ovarian stimulation
Rate of oocyte retrieval (%) 69.8 63.0 0.40
COCs retrieved 1.6 ± 1.1 3.5 ± 3.4 0.01*
Maturation rate in ICSI (%, n) 33.3 (1/3) 77.8 (7/9) 0.24
Fertilization rate by ICSI (%, n) 100.0 (1/1) 100 (7/7) /
Fertilization rate by IVF (%, n) 76.5 (26/34) 73.2 (52/71) 0.72
Clinical outcome
Embryos transferred 2.0 ± 0 2.1 ± 0.3 0.40
Implantation rate (%, n) 25 (1/4) 28.0 (7/25) 1.00
Clinical pregnancy rate (%, n) 50.0 (1/2) 33.3 (4/12) 1.00
Spontaneous abortion rate (%) 0 0
The percentage data were analyzed by Chi-square test or Fisher's exact test, whereas
other data were analyzed with independent t test.
*p < 0.05.
COCs ¼ cumulus oocyte complexes; ICSI ¼ intracytoplasmic sperm injection;
IVF ¼ in vitro fertilization.
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rate by IVF was signiﬁcantly increased in the LPOS group (Table 1).
There were no signiﬁcant differences in the fertilization rate by ICSI
or in the number of transferable embryos between the two groups
(Table 1). More importantly, the pregnancy rate in the LPOS group
(46.4%) was signiﬁcantly higher than that in the GnRH-ant group
(overall, 25.8%; p ¼ 0.04) with the use of fresh embryos (22.9%,
p¼ 0.03) as well as frozen embryos (29.6%, p¼ 0.15) (Table 2). There
were no signiﬁcant differences in the implantation rate of D3 or D5
embryos, and the miscarriage rate between the two groups
(Table 2).
Comparison of clinical parameters of oocytes retrieved during the
follicular phase and luteal phase
To further verify the efﬁcacy of the LPOS protocol, we compared
the clinical characteristics of oocytes retrieved during the follicular
phase using mild stimulation and the luteal phase in the same cycle
of PORs undergoing LPOS treatment. There were no signiﬁcant
differences in the rates of maturation, fertilization, implantation,
and pregnancy between the follicular phase and luteal phase
(p > 0.05, Table 3). However, the numbers of retrieved oocytes and
transferable embryos from the luteal phase were signiﬁcantly
higher than those from the follicular phase (p < 0.05, Table 3).
Discussion
In the present study, we compared the clinical outcomes of
LPOS and GnRH-ant regimes in PORs. Although the AFC in theLPOS group was signiﬁcantly lower than that in the GnRH-ant
group, the numbers of retrieved oocytes and transferable em-
bryos were not signiﬁcantly different between the two regimes.
More importantly, the pregnancy rate in the LPOS group was
signiﬁcantly higher than that in the GnRH-ant group. These
data indicate that LPOS is a feasible and possibly better
regimen for the treatment of PORs compared to the GnRH-ant
protocol.
The wave theory of follicle development proposes that antral
follicles at the luteal phase may not regress, but instead develop to
maturity after appropriate stimulation. This possibility has been
veriﬁed in animals and humans [10,16]. Recently, Kuang et al [12]
reported that the clinical pregnancy rate, ongoing pregnancy rate,
and implantation rate of frozen embryos obtained from LPOS were
55.46%, 48.91%, and 40.37%, respectively, in normal response
women, and 56.5% (13/23), 47.8% (11/23), and 36.6% (15/41),
respectively, in PORs who underwent double stimulations (follicle
phase stimulation and luteal phase stimulation) within one men-
strual cycle [13]. These data suggest that LPOS is feasible for
infertile women, especially for PORs.
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The conventional protocols usually start during the menstrual
period and easily cause nonsynchronous growth of follicles [3,5]. In
the luteal phase, the P and inhibin A secreted from the corpus
luteum can inhibit the development of a dominant follicle, but
exogenous Gn can induce synchronous growth of a group of folli-
cles [17]. Thus, ovarian stimulation in the luteal phase may achieve
a greater number of high-quality oocytes. This may help to explain
why a signiﬁcantly lower AFC number was observed in the LPOS
group, but the numbers of oocytes retrieved and available embryos
were similar to those in the GnRH-ant group in our study. In
addition, the LH peak is not present after LPOS treatment. In the
conventional protocols for ovarian stimulation, hCG administration
must be given prior to the LH surge, and thus, the LH level must be
carefully monitored [3,4]. Compared with the conventional GnRH-
ant protocol, the LH level in the LPOS group was signiﬁcantly
reduced; 9.5% of PORs in the GnRH-ant group had an LH 10 IU/L
compared to none in the LPOS group. Therefore, it is easier to
control hCG administration and oocyte retrieval in the LPOS regime.
Importantly, the LPOS procedure allows us to retrieve oocytes twice
in one cycle. The lower number of oocytes is the major issue in
PORs, and thus, it is critical to collect more high-quality oocytes for
subsequent embryo transfer.
In this study, we retrieved more oocytes from LPOS-treated
PORs, but the rate of oocyte retrieval in the LPOS group was
signiﬁcantly lower than that in the GnRH-ant group. Although our
ﬁnding is similar to that reported in Kuang et al's study (65.5%) [12],
the possible reason for the lower rate of oocyte retrieval is associ-
ated with repeated oocyte retrieval in one cycle, because the corpus
luteum cysts formed after oocyte retrieval in the follicular phase
will be easily considered as follicles during oocyte retrieval in the
luteal phase. However, there are a few limitations in this study.
First, this is a retrospective study, and all ﬁndings need to be
veriﬁed in perspective studies with a large cohort of PORs. Second,
we used two different medicines in the LPOS procedure, which
makes the procedure complex. Third, epidemiologic studies have
shown better clinical outcomes in frozen embryo transfer cycles
compared with fresh IVF cycles, because multiple corpus lutea may
secrete high levels of hormones and other factors that can affect the
endometrium and the implanting embryo during a fresh IVF cycle
[18]. In our study, we compared frozen embryos to fresh embryos,
which may be a bias of the data. Additionally, the cancelation rate
was similar between the two groups owing to a lack of transferable
embryos.
In conclusion, compared with the conventional GnRH-ant pro-
tocol, the LPOS protocol can increase the numbers of retrieved
oocytes and transferable embryos as well as the pregnancy rate.
Thus, LPOS may be a better procedure for PORs.Conﬂicts of interest
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